Down-regulation of osteopontin attenuates breast tumour progressionin vivo
Open Access
- 6 February 2008
- journal article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 12 (6a), 2305-2318
- https://doi.org/10.1111/j.1582-4934.2008.00263.x
Abstract
Development of breast tumour malignancies results in enhanced expression of various oncogenic molecules. Elevated expression of osteopontin (OPN) in higher grades of breast carcinoma correlates with enhanced expressions of several oncogenic molecules (urokinase-type plasminogen activator [uPA], matrix metalloproteinase-2/-9 [MMP-2 and -9]) and increased angiogenic potential of breast carcinoma. In this study, using in vitro and multiple in vivo models, we have demonstrated that silencing of OPN by its specific small interfering RNA (siRNA) down-regulates the expressions of oncogenic molecules such as uPA, MMP-2 and -9 resulting in inhibition of in vitro cell motility and in vivo tumourigenicity in mice. Moreover our results demonstrated that OPN−/− mice showed slower progression of tumour growth in breast cancer model as compared to wild-type mice. Furthermore, the data showed that injection of carcinogenic compound, pristane (2, 6,10,14-tetramethylpen-tadecane) induces breast tumour progression leading to enhanced expression of OPN and other oncogenic molecules in mammary fat pad of nude- and wild-type mice but not in OPN−/ mice. However, intratumoural injection of OPN siRNA to pristane-induced tumour significantly suppressed these effects. Our data revealed that knocking down of OPN effectively curb breast cancer progression and further suggested that developing of OPN-based therapeutics might be an emerging approach for the next generation of breast cancer management.Keywords
This publication has 48 references indexed in Scilit:
- Angiogenesis: an organizing principle for drug discovery?Nature Reviews Drug Discovery, 2007
- Override of the Osteoclast Defect in Osteopontin-Deficient Mice by Metastatic Tumor Growth in the BoneThe American Journal of Pathology, 2006
- Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve PrognosisJNCI Journal of the National Cancer Institute, 2006
- Osteopontin: role in cell signaling and cancer progressionTrends in Cell Biology, 2006
- Prostaglandin E2 receptors EP2 and EP4 are up-regulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-α and IL-6 productionJournal of Leukocyte Biology, 2004
- Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cellsCancer Gene Therapy, 2003
- Swelling‐activated, cystic fibrosis transmembrane conductance regulator‐augmented ATP release and Cl− conductances in murine C127 cellsThe Journal of Physiology, 2000
- Inhibitory effect of antisense epidermal growth factor receptor RNA on the proliferation of rat C6 glioma cells in vitro and in vivoJournal of Neurosurgery, 2000
- Analysis of transcriptional activation of a cyclic AMP response element by 2,6,10,14‐tetramethylpentadecane (pristane) in JB6 mouse epidermal cellsMolecular Carcinogenesis, 1994
- Induction of Plasma Cell Tumours in BALB/c Mice with 2,6,10,14-Tetramethylpentadecane (Pristane)Nature, 1969